Table 2 Surgery

From: Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO)

 

ICT group (n = 45)

CRT group (n = 39)

Type of esophagectomy, n (%)

Mckeown

44 (97.8)

38 (97.4)

Ivor Lewis

0

1 (2.6)

Transhiatal

1 (2.2)

0

Others

0

0

Resection grade, n (%, 95% CI)

R0

45 (100.0, 92.13–100.00)

39 (100.0, 90.97–100.00)

R1

0 (0, 0–7.87)

0 (0, 0–9.03)

R2

0 (0, 0–7.87)

0 (0, 0–9.03)

Operative time (min), median (range)

315 (150, 480)

300 (90, 558)

Blood loss (ml), median (range)

200 (100, 600)

200 (50, 1000)

Length of hospital stay (day), median (range)

8 (6, 20)

8 (1, 23)

Number of lymph nodes removed (n), median (range)

45 (13, 97)

42 (11, 88)

30-day mortality after surgery, n (%)

0

2 (5.1)

90-day mortality after surgery, n (%)

0

2 (5.1)

  1. ICT neoadjuvant immunochemotherapy, CRT neoadjuvant chemoradiotherapy.